PMID- 10691928
OWN - NLM
STAT- MEDLINE
DCOM- 20000424
LR  - 20190513
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 119
IP  - 3
DP  - 2000 Mar
TI  - Human monoclonal anti-phospholipid antibodies selectively bind to membrane 
      phospholipid and beta2-glycoprotein I (beta2-GPI) on apoptotic cells.
PG  - 533-43
AB  - The ability of an anti-phospholipid (LJ1) and an anti-beta2-GPI (RSP-57) human 
      MoAb to bind to apoptotic but not viable cells was demonstrated in this study. 
      Both MoAbs were derived from patients with systemic lupus erythematosus and 
      anti-phospholipid antibody syndrome. The parallel analysis of the specificity and 
      affinity of four anti-phospholipid human MoAbs suggests that the binding of LJ1 
      MoAb to apoptotic cells is a specific property of this MoAb. RSP-57 MoAb 
      recognizes apoptotic cells through beta2-GPI which becomes available for binding 
      after the interaction with negatively charged phospholipids. This observation 
      provides evidence that the binding of human anti-phospholipid antibodies to 
      apoptotic cells occurs in both a beta2-GPI-dependent and independent way and 
      involves a restricted group of epitopes. The finding that LJ1 and RSP-57 MoAbs 
      bind apoptotic cells underlines the property of these MoAbs to act as cell 
      membrane markers of apoptosis. Major pathological implications derive from the 
      observation that LJ1 and RSP-57 MoAbs recognize epitopes expressed on 'early' 
      apoptotic cells. The interference with the in vivo clearance and processing of 
      apoptotic cells is a potential pathogenic mechanism of these antibodies.
FAU - Pittoni, V
AU  - Pittoni V
AD  - Centre for Rheumatology/Bloomsbury Rheumatology Unit, Department of Medicine and 
      Department of Haematology, University College London, London, UK.
FAU - Ravirajan, C T
AU  - Ravirajan CT
FAU - Donohoe, S
AU  - Donohoe S
FAU - MacHin, S J
AU  - MacHin SJ
FAU - Lydyard, P M
AU  - Lydyard PM
FAU - Isenberg, D A
AU  - Isenberg DA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Glycoproteins)
RN  - 0 (Membrane Lipids)
RN  - 0 (Phospholipids)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
MH  - Animals
MH  - Antibodies, Antiphospholipid/*immunology
MH  - Antibodies, Monoclonal/*immunology
MH  - Antibody Specificity
MH  - Apoptosis/*immunology
MH  - Flow Cytometry
MH  - Glycoproteins/*immunology
MH  - Humans
MH  - Membrane Lipids/immunology
MH  - Mice
MH  - Phospholipids/*immunology
MH  - U937 Cells
MH  - beta 2-Glycoprotein I
PMC - PMC1905581
EDAT- 2000/02/26 09:00
MHDA- 2000/04/29 09:00
PMCR- 2001/03/01
CRDT- 2000/02/26 09:00
PHST- 2000/02/26 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/02/26 09:00 [entrez]
PHST- 2001/03/01 00:00 [pmc-release]
AID - cei1161 [pii]
AID - 10.1046/j.1365-2249.2000.01161.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2000 Mar;119(3):533-43. doi: 10.1046/j.1365-2249.2000.01161.x.